RGS14 and glioma: COL17A1’s role in ECM remodeling and invasion has been supported by integrated analyses identifying it as a potential biomarker of glioblastoma multiforme [26], while RGS14’s involvement in immune regulation and prognosis has been confirmed through machine learning studies unveiling immune-related signatures in multicenter glioma research [27].